Skip survey header

Diabetes/Weight Loss Medications – Impact on Your Practice Survey

Please tell us your experience dispensing glucagon-like peptide-1 drugs (i.e. GLP-1 agonists sometimes categorized as “incretin mimetics”) (e.g. Ozempic, Trulicity, Victoza, etc.) indicated for the treatment of type 2 diabetes or weight loss (e.g. Wegovy, Saxenda). Their use has dramatically increased in popularity because of the weight loss benefits that many patients are experiencing. Many patients without type 2 diabetes are obtaining prescriptions for these medications for weight loss due to coverage exclusion for GLP-1 agonists indicated for weight management.

Pharmacies are being affected by the explosion in the popularity of these high dollar medications in a variety of ways, e.g. navigating supply shortages, struggling with insurance coverage, inventory cash flow,  and keeping up with the changing landscape of the patient assistance coupons and waiting to get paid by these coupons. 

NCPA is conducting a brief, 5-minute survey on the GLP-1 agonists so it can best represent its members interests to media, legislators, and others in the industry on these popular medications.


 
Note:
As you read and answer the following questions, please consider the following list below, which contains the currently available GLP-1 agonists that are currently on the market:  
  • Dulaglutide (Trulicity)
  • Exenatide (Bydureon & Byetta)
  • Semaglutide (Ozempic & Wegovy)
  • Liraglutide (Victoza & Saxenda)
  • Tirzepatide (Mounjaro)
  • Semaglutide oral (Rybelsus)
1. Do you stock and sell any GLP-1 agonists?
2. In the last quarter, have you seen an increase from the previous quarter in patient interest in obtaining a prescription for a GLP-1 agonist?
3. In the last quarter, have you seen an increase in the number of GLP-1 agonist prescriptions you are receiving from prescribers?
4. What percentage of your GLP-1 agonist prescriptions are from the following types of prescribers?  Estimate the percentage of each.  (must total 100%):
0 out of 100% Total
This question requires a valid percent format.
%
This question requires a valid percent format.
%
7. Did you experience any order shortages or backorders of any of the GLP-1 agonists in the third quarter of 2023?
If so, for which drugs are you experiencing a shortage?
8. Do you offer compounding services for semaglutide injectable prescriptions?
9. What percentage of your GLP-1 agonist prescriptions are paid by the following payers?  Estimate the percentage of each.  (must total 100%):
 
0 out of 100% Total
This question requires a valid percent format.
%
This question requires a valid percent format.
%
This question requires a valid number format.
# of weeks
13. Have you been paid below your cost to acquire the drug for some GLP-1 agonist prescriptions since the first of the year?
This question requires a valid percent format.
%
When you are paid below cost for a GLP-1 agonist prescription, what is the average dollar amount you are paid below your acquisition cost? This question requires a valid currency format.
If so, which GLP-1 agonists are you most often reimbursed below your acquisition cost?
14. Has your primary pharmaceutical wholesaler recently changed how they price the GLP-1 agonists, resulting in a higher acquisition cost to you?
If so, which wholesaler do you use? 
15. Have you had to turn a patient away from your pharmacy because of lack of availability of a GLP-1 agonist product?
16. Have you had to turn a patient away from your pharmacy because you were losing money on a GLP-1 agonist product?
17. Are you considering no longer filling some GLP-1 agonists because of low reimbursement?
This question requires a valid percent format.
%
This question requires a valid number format.
0%